BioPharma Resources

Drug Trial Radar · NCT07839884

A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time

A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF TILREKIMIG IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,360

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Apr 21, 2034

Study completion Apr 21, 2034

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Continuation Study of Tilrekimig in Adults with Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About this Medicine when Used for a Long Period of Time.

Conditions

  • Moderate to Severe Chronic Obstructive Pulmonary Disease

Interventions

  • TilrekimigDrug

    SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events During Treatment Period 1 (TP1)Time frame: Up to 60 weeks
  2. Number of Participants With Treatment-Emergent Serious Adverse Events During Treatment Period 1Time frame: Up to 60 weeks
  3. Number of Participants With Treatment-Emergent Adverse Events Leading to Permanent Discontinuation of Study Intervention During Treatment Period 1Time frame: Up to 60 weeks
  4. Number of Participants With Clinically Significant Laboratory Abnormalities During Treatment Period 1Time frame: Up to 60 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Institute of HealthCare Assessment d/b/a Apex Clinical Research

    San Diego, California · Recruiting

  • Southeastern Research Center

    Winston-Salem, North Carolina · Recruiting

  • Clinical Research Associates of Central PA

    DuBois, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.